| Cell line name |
HUH7-R-LUC |
|---|
| Accession |
CVCL_B7TJ |
|---|
| Resource Identification Initiative |
To cite this cell line use: HUH7-R-LUC (RRID:CVCL_B7TJ) |
|---|
| Comments |
Population: Japanese.
Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar).
Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P08659; Firefly luciferase.
Genetic integration: Method=Transfection/transduction; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
Derived from site: In situ; Liver; UBERON=UBERON_0002107. |
|---|
| Sequence variations |
- Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line).
- Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Adult hepatocellular carcinoma (NCIt: C7956)
Adult hepatocellular carcinoma (ORDO: Orphanet_210159) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_B7TI (HUH7-R) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
57Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | DOI=10.5282/edoc.26548
Messner M.
Sorafenib resistance of hepatocellular carcinoma: antibiotics second- line to sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption.
Thesis PhD (2020); Ludwig Maximilians University of Munich; Munich; Germany PubMed=32652772; DOI=10.1096/fj.202001128R
Messner M., Schmitt S., Ardelt M.A., Frohlich T., Muller M., Pein H., Huber-Cantonati P., Ortler C., Koenig L.M., Zobel L., Koeberle A., Arnold G.J., Rothenfusser S., Kiemer A.K., Gerbes A.L., Zischka H., Vollmar A.M., Pachmayr J.
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
FASEB J. 34:11860-11882(2020) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_B7TJ
|
|---|
| Encyclopedic resources |
Wikidata; Q112929800
|
|---|
| Entry history |
|---|
| Entry creation | 23-Jun-2022 |
|---|
| Last entry update | 10-Sep-2024 |
|---|
| Version number | 7 |
|---|
